title: Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction.
abstract: Myocardial infarction (MI) is the main cause for the progression of the left ventricle towards congestive heart failure. The optimal healing after MI requires timely induction and resolution of inflammation. Primarily, there have been a number of strategies applied to inhibit the post-MI inflammation but approaches that focus on the resolution of inflammation have sparsely been used in the treatment of heart failure. The early attempts to inhibit post-MI inflammation resulted in adverse outcomes that were realized in heart failure trials. We provide here an overview on the cyclooxygenase (COX)- and lipoxygenase (LOX)-derived lipid mediators that are either impairing or resolving the post-MI inflammation. With the evolution of lipidomics there has been emerging novel bioactive-specialized lipid mediators that promise to resolve chronic inflammation rather than promoting inhibition. The current review is focused on post-MI immune cells kinetics and the unexplored array of lipid mediators that are coordinated by COX and LOX. Thus, an emphasis on COX and LOX poses key questions and potential for the development of novel targets in the heart failure treatment strategy. This updated dynamic approach aims to fuse basic pre-clinical discoveries and translational bioactive lipid-based resolvin discoveries that could be potentially used in the clinic for the treatment of heart failure.
authors.affiliation: Division of Cardiovascular Disease, Department of Medicine, The University of Alabama at Birmingham, 703 19th Street South, Birmingham, AL, 35233, USA.
authors.forename: Vasundhara
authors.initials: V
authors.lastname: Kain
authors.forename: Sumanth D
authors.initials: SD
authors.lastname: Prabhu
authors.forename: Ganesh V
authors.initials: GV
authors.lastname: Halade
mesh_terms: D000818:Animals; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D008055:Lipids / Q000502:physiology; D008084:Lipoxygenase / Q000502:physiology; D009203:Myocardial Infarction / Q000150:complications* / Q000276:immunology; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology; D020257:Ventricular Remodeling
chemical_list: D008055:Lipids; D008084:Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases